Olistico Wealth LLC Sells 205 Shares of Danaher Co. (NYSE:DHR)

Olistico Wealth LLC lowered its stake in shares of Danaher Co. (NYSE:DHR) by 39.7% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 311 shares of the conglomerate’s stock after selling 205 shares during the period. Olistico Wealth LLC’s holdings in Danaher were worth $86,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in DHR. Tsfg LLC boosted its stake in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher in the 2nd quarter worth approximately $25,000. nVerses Capital LLC purchased a new position in shares of Danaher in the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC purchased a new position in shares of Danaher in the 1st quarter worth approximately $30,000. Finally, Richardson Financial Services Inc. purchased a new position in shares of Danaher in the 4th quarter worth approximately $42,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

DHR has been the topic of a number of research analyst reports. Robert W. Baird boosted their target price on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Barclays boosted their target price on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. Evercore ISI upped their price objective on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus upped their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Finally, TD Cowen upped their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $282.12.

Danaher Price Performance

DHR stock opened at $268.81 on Wednesday. The firm has a 50 day moving average price of $271.01 and a 200-day moving average price of $258.75. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The firm has a market capitalization of $199.10 billion, a price-to-earnings ratio of 45.56, a PEG ratio of 4.55 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the business earned $2.05 EPS. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis. Equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 39,659 shares of company stock valued at $11,042,433. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.